Clinical trial
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and…
NCT00065351 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00065351 |
|---|---|
| Title | Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma |
| Official title | A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 222 |
| Start date | Jul 1, 2003 |
| Primary completion | Oct 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Jul 23, 2003 |
| Last update posted | Nov 12, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: